首页> 外文期刊>Current therapeutic research, clinical and experimental. >The New Oral Anticoagulants for the Treatment of Venous Thromboembolism: A New Paradigm Shift in Antithrombotic Therapy
【24h】

The New Oral Anticoagulants for the Treatment of Venous Thromboembolism: A New Paradigm Shift in Antithrombotic Therapy

机译:治疗静脉血栓栓塞的新型口服抗凝药:抗血栓治疗的新范式转变

获取原文
获取原文并翻译 | 示例
       

摘要

Background: Several novel oral anticoagulants have been studied for the prevention and treatment of venous thromboembolism (VTE) in different patient populations. Clinicians will increasingly encounter scenarios in which they must choose among these and conventional anticoagulants for the treatment of this potentially fatal condition.Objective: To review the results of Phase III clinical trials that investigated the novel oral anticoagulants for the treatment of deep vein thrombosis and pulmonary embolism. Potential advantages and disadvantages of these anticoagulant agents with respect to each other and conventional therapy will also be explored through a case-based approach.Methods: A literature search in PubMed was conducted that identified Phase HI clinical trials investigating the novel oral anticoagulant agents for the treatment of VTE.
机译:背景:已经研究了几种新型的口服抗凝剂,用于预防和治疗不同患者人群的静脉血栓栓塞(VTE)。临床医生将越来越多地遇到必须在这些抗凝剂和常规抗凝剂之间进行选择以治疗这种潜在致命疾病的方案。目的:回顾用于治疗新型深静脉血栓形成和肺部疾病的口服抗凝剂的III期临床试验结果栓塞。这些抗凝药相对于传统疗法的优缺点也将通过基于案例的方法进行探讨。方法:在PubMed中进行了文献检索,确定了HI期临床试验,研究了针对这种抗凝药的新型口服抗凝药VTE的治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号